100
Participants
Start Date
June 7, 2021
Primary Completion Date
March 30, 2024
Study Completion Date
March 30, 2024
Fluciclovine PET guided Radiotherapy
PET+MRI Based There is no GTV\_5400. The GTV\_6000 will be defined as the surgical cavity inclusive of any remaining tumor enhancement and the hypermetabolic volume. CTV\_5400 will include the GTV\_6000 plus a margin of 1.0 cm which may be reduced around natural barriers to tumor growth such as the skull, ventricles, falx, etc. CTV\_5400 must also include the entirety of the GTV\_6000. There is no CTV\_6000. PTV\_5400 is the CTV\_5400 plus a geometric 3 mm expansion in all dimensions; PTV\_6000 is GTV\_6000 plus a geometric 3 mm expansion in all dimensions. PTV may extend beyond bony margins and the skin surface. The PTV\_5400 must contain the PTV\_6000. In the setting of multi-focal disease, the primary target volumes will be defined as above, but for satellite lesions, the GTV\_6000 will be defined as any tumor enhancement and hypermetabolic volume. There will be no CTV\_6000. PTV\_6000 will be defined as GTV\_6000 plus a geometric 3 mm expansion in all dimensions.
RECRUITING
St. Joseph's Hospital and Medical Center, Phoenix
Collaborators (1)
Barrow Neurological Foundation
OTHER
Arizona Biomedical Research Commission (ABRC)
OTHER
Blue Earth Diagnostics
INDUSTRY
St. Joseph's Hospital and Medical Center, Phoenix
OTHER